IL255405B - Use of a polypeptide to induce an immune signal and/or to influence the activity of the intestinal barrier and/or to regulate a metabolic state - Google Patents
Use of a polypeptide to induce an immune signal and/or to influence the activity of the intestinal barrier and/or to regulate a metabolic stateInfo
- Publication number
- IL255405B IL255405B IL255405A IL25540517A IL255405B IL 255405 B IL255405 B IL 255405B IL 255405 A IL255405 A IL 255405A IL 25540517 A IL25540517 A IL 25540517A IL 255405 B IL255405 B IL 255405B
- Authority
- IL
- Israel
- Prior art keywords
- polypeptide
- barrier function
- intestinal barrier
- metabolic status
- immune signalling
- Prior art date
Links
- 230000007358 intestinal barrier function Effects 0.000 title 1
- 235000020938 metabolic status Nutrition 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166598 | 2015-05-06 | ||
| PCT/EP2016/060033 WO2016177797A1 (en) | 2015-05-06 | 2016-05-04 | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL255405A0 IL255405A0 (en) | 2017-12-31 |
| IL255405B true IL255405B (en) | 2022-01-01 |
Family
ID=74184294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255405A IL255405B (en) | 2015-05-06 | 2017-11-02 | Use of a polypeptide to induce an immune signal and/or to influence the activity of the intestinal barrier and/or to regulate a metabolic state |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10738089B2 (enExample) |
| EP (1) | EP3292135B1 (enExample) |
| JP (1) | JP6894382B2 (enExample) |
| KR (1) | KR102736980B1 (enExample) |
| CN (1) | CN107980043B (enExample) |
| AU (2) | AU2016257315A1 (enExample) |
| DK (1) | DK3292135T3 (enExample) |
| EA (1) | EA201700507A1 (enExample) |
| ES (1) | ES2934138T3 (enExample) |
| HK (1) | HK1252412A1 (enExample) |
| IL (1) | IL255405B (enExample) |
| MX (1) | MX390092B (enExample) |
| PL (1) | PL3292135T3 (enExample) |
| WO (1) | WO2016177797A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703395PA (en) | 2014-10-31 | 2017-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3292135B1 (en) | 2015-05-06 | 2022-09-21 | Wageningen Universiteit | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
| PL3626081T3 (pl) * | 2015-09-10 | 2022-04-25 | Université Catholique de Louvain | Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych |
| WO2018165338A2 (en) * | 2017-03-07 | 2018-09-13 | uBiome, Inc. | Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof |
| US20200246488A1 (en) * | 2017-07-17 | 2020-08-06 | The Broad Institute, Inc. | Compositions and methods for treating inflammatory bowel diseases |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| EP3823651A4 (en) | 2018-07-19 | 2022-04-27 | Pendulum Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION |
| KR102340392B1 (ko) * | 2018-10-08 | 2021-12-17 | 한국생명공학연구원 | 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도 |
| KR102197180B1 (ko) | 2018-10-11 | 2020-12-31 | 주식회사 고바이오랩 | 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물 |
| CN110079474B (zh) * | 2019-04-12 | 2022-11-25 | 沈阳药科大学 | 一种高密度培养艾克曼嗜黏蛋白菌的方法 |
| KR102263030B1 (ko) * | 2019-05-07 | 2021-06-10 | 한국생명공학연구원 | 염증성 장질환의 예방 또는 치료용 펩타이드 |
| CN110227085A (zh) * | 2019-07-16 | 2019-09-13 | 江苏省中医院 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
| EP4079837A4 (en) * | 2019-09-25 | 2024-06-05 | HealthBiome, Inc. | OBLIGATE ANAEROBIC HUMAN INTESTINAL MICROBES FOR CANCER TREATMENT AND ITS USE |
| KR102397916B1 (ko) * | 2019-10-01 | 2022-05-17 | (주)헬스바이옴 | 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법 |
| CN110950937B (zh) * | 2019-11-25 | 2021-05-04 | 安徽大学 | 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用 |
| CN115315433A (zh) * | 2020-01-10 | 2022-11-08 | 黄志宏 | Tlr2交互作用的胜肽以及包括其的组合物 |
| KR102671044B1 (ko) * | 2020-03-25 | 2024-05-31 | 한국생명공학연구원 | 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도 |
| US20210322492A1 (en) * | 2020-04-16 | 2021-10-21 | Amucin Oy Ltd | Probiotic strains and uses thereof |
| CN111690044B (zh) * | 2020-05-06 | 2022-03-01 | 中南大学湘雅二医院 | Amuc1100蛋白的用途 |
| AU2021299904A1 (en) | 2020-07-01 | 2023-01-19 | Advanced Microbiome Interventions B.V. | Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
| WO2022098051A1 (ko) * | 2020-11-05 | 2022-05-12 | 한국생명공학연구원 | 항염 및 조직 재생작용을 갖는 신규 펩타이드 |
| CN113413466B (zh) * | 2020-12-15 | 2022-08-19 | 和度生物医药(上海)有限公司 | 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法 |
| CN115364198A (zh) * | 2022-08-23 | 2022-11-22 | 广州康泽医疗科技有限公司 | 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用 |
| CN116059254B (zh) * | 2023-02-27 | 2025-04-18 | 广州知易生物科技有限公司 | 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用 |
| KR102835266B1 (ko) | 2023-09-11 | 2025-07-17 | 충남대학교산학협력단 | 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도 |
| CN117304264B (zh) * | 2023-11-27 | 2024-02-06 | 中国科学院烟台海岸带研究所 | 一种具有肠屏障保护功能的五肽rp5及其应用 |
| CN118063567B (zh) * | 2024-03-03 | 2025-11-21 | 吉林大学 | 一种用于炎性肠病治疗的重组蛋白的制备与应用 |
| CN119874827B (zh) * | 2025-03-27 | 2025-06-13 | 杭州康源食品科技有限公司 | 一种具有免疫调节作用的九肽及其制备和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
| NL1014380C2 (nl) | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
| US7253333B2 (en) * | 2001-02-28 | 2007-08-07 | National Institute Of Advanced Industrial Science And Technology | Drosophila strain carrying bradeion gene(s) transferred thereinto |
| EP1583548A4 (en) * | 2002-12-10 | 2007-10-17 | Epimmune Inc | HLA-A1, A2 -A3, -A24, -B7 AND B44TUMOR ASSOCIATED ANTIGENPEPTIDES AND COMPOSITIONS |
| US20050180962A1 (en) | 2003-01-30 | 2005-08-18 | Eyal Raz | Inactivated probiotic bacteria and methods of use thereof |
| WO2005030133A2 (en) * | 2003-09-22 | 2005-04-07 | Yale University | Treatment with agonists of toll-like receptors |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| US7812121B2 (en) | 2006-08-31 | 2010-10-12 | Baker Audrey E | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
| WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
| EP2030623A1 (en) | 2007-08-17 | 2009-03-04 | Nestec S.A. | Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria |
| FR2944524B1 (fr) | 2009-04-17 | 2012-11-30 | Ipsen Pharma Sas | Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament |
| CA2761444C (en) | 2009-05-11 | 2018-04-24 | Nestec S.A. | Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders |
| WO2011137369A1 (en) * | 2010-04-29 | 2011-11-03 | The Regents Of The University Of California | Production of gamma-aminobutyric acid by recombinant microorganisms |
| US9104670B2 (en) | 2010-07-21 | 2015-08-11 | Apple Inc. | Customized search or acquisition of digital media assets |
| WO2012052868A2 (en) | 2010-10-20 | 2012-04-26 | Koninklijke Philips Electronics N.V. | Disaggregation apparatus |
| EP2449891A1 (en) | 2010-11-05 | 2012-05-09 | Nestec S.A. | Drinking yoghurt preparations containing non-replicating probiotic micro-organisms |
| ES2565407T3 (es) | 2010-11-05 | 2016-04-04 | Nestec S.A. | Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| WO2014075745A1 (en) | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| KR101740893B1 (ko) * | 2014-05-20 | 2017-06-13 | 주식회사 엠디헬스케어 | Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 |
| EP3292135B1 (en) | 2015-05-06 | 2022-09-21 | Wageningen Universiteit | Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status |
| PL3626081T3 (pl) | 2015-09-10 | 2022-04-25 | Université Catholique de Louvain | Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych |
| US11071626B2 (en) | 2018-03-16 | 2021-07-27 | W. L. Gore & Associates, Inc. | Diametric expansion features for prosthetic valves |
-
2016
- 2016-05-04 EP EP16724321.1A patent/EP3292135B1/en active Active
- 2016-05-04 CN CN201680026195.4A patent/CN107980043B/zh active Active
- 2016-05-04 KR KR1020177035003A patent/KR102736980B1/ko active Active
- 2016-05-04 PL PL16724321.1T patent/PL3292135T3/pl unknown
- 2016-05-04 EA EA201700507A patent/EA201700507A1/ru unknown
- 2016-05-04 MX MX2017014111A patent/MX390092B/es unknown
- 2016-05-04 ES ES16724321T patent/ES2934138T3/es active Active
- 2016-05-04 US US15/571,175 patent/US10738089B2/en active Active
- 2016-05-04 DK DK16724321.1T patent/DK3292135T3/da active
- 2016-05-04 WO PCT/EP2016/060033 patent/WO2016177797A1/en not_active Ceased
- 2016-05-04 HK HK18111709.9A patent/HK1252412A1/zh unknown
- 2016-05-04 AU AU2016257315A patent/AU2016257315A1/en not_active Abandoned
- 2016-05-04 JP JP2017557983A patent/JP6894382B2/ja active Active
-
2017
- 2017-11-02 IL IL255405A patent/IL255405B/en unknown
-
2020
- 2020-06-30 US US16/916,459 patent/US11466057B2/en active Active
- 2020-11-11 AU AU2020267210A patent/AU2020267210B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX390092B (es) | 2025-03-11 |
| CN107980043A (zh) | 2018-05-01 |
| KR20180011130A (ko) | 2018-01-31 |
| EA201700507A1 (ru) | 2018-05-31 |
| AU2020267210A1 (en) | 2020-12-17 |
| ES2934138T3 (es) | 2023-02-17 |
| IL255405A0 (en) | 2017-12-31 |
| HK1252412A1 (zh) | 2019-05-24 |
| NZ737765A (en) | 2024-08-30 |
| AU2016257315A1 (en) | 2017-11-23 |
| US20180265554A1 (en) | 2018-09-20 |
| WO2016177797A1 (en) | 2016-11-10 |
| US10738089B2 (en) | 2020-08-11 |
| DK3292135T3 (da) | 2022-10-31 |
| MX2017014111A (es) | 2018-02-26 |
| AU2020267210B2 (en) | 2023-10-12 |
| PL3292135T3 (pl) | 2023-01-02 |
| KR102736980B1 (ko) | 2024-12-02 |
| JP2018515502A (ja) | 2018-06-14 |
| EP3292135B1 (en) | 2022-09-21 |
| JP6894382B2 (ja) | 2021-06-30 |
| EP3292135A1 (en) | 2018-03-14 |
| BR112017023751A2 (pt) | 2018-07-31 |
| CN107980043B (zh) | 2021-09-24 |
| CA2984985A1 (en) | 2016-11-10 |
| US11466057B2 (en) | 2022-10-11 |
| US20210147489A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255405B (en) | Use of a polypeptide to induce an immune signal and/or to influence the activity of the intestinal barrier and/or to regulate a metabolic state | |
| PT3292135T (pt) | Uso de um polipéptido para efetuar a sinalização imunitária e/ou afetar a função de barreira intestinal e/ou regular o estado metabólico | |
| IL252812B (en) | Pyrin polypeptide and immune modulation | |
| HUE068462T2 (hu) | Dobozfedél | |
| PL3687634T3 (pl) | Maska pełnotwarzowa | |
| IL250571B (en) | coupling and gasket | |
| GB2561542B (en) | Ampoule closure | |
| AU363846S (en) | Closure | |
| SG11202001400YA (en) | Closure | |
| IL247551B (en) | A peptide drug in the form of a dry powder | |
| ZA201704991B (en) | Container closure systems | |
| ZA201800643B (en) | Closure system | |
| ZA201905760B (en) | Tamper evident closure | |
| AU363132S (en) | Closure | |
| PL3679987T3 (pl) | Przegroda ognioodporna | |
| AP00995S1 (en) | Security seal | |
| PH32018000900S1 (en) | Security seal | |
| GB201708099D0 (en) | Closure | |
| AU201711445S (en) | Closure | |
| GB2537810B (en) | Flexible seal | |
| GB201522995D0 (en) | A closure system | |
| PL3163132T3 (pl) | Urządzenie do uszczelniania oraz system do nakładania zawierający takie urządzenie | |
| GB201506785D0 (en) | Face mask and face seal component | |
| GB201504273D0 (en) | Overhood seal and use thereof | |
| GB201421519D0 (en) | A flood barrier system and a barrier thereof |